证券代码：300937 证券简称：药易购 公告编号：2024-042 四川合纵药易购医药股份有限公司 第三届监事会第十八次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 四川合纵药易购医药股份有限公司（以下简称"公司"）第三届监事会第十八 次会议于 2024 年 11 月 22 日在公司会议室以现场方式召开。本次监事会会议的 通知于 2024 年 11 月 15 日以书面、电话方式通知全体监事。会议应出席监事 3 名，实际出席监事 3 名。本次监事会会议由监事会主席田文书先生主持。本次会 议的召集和召开符合国家有关法律、行政法规、部门规章、规范性文件及《四川 合纵药易购医药股份有限公司章程》的规定。 二、监事会会议审议情况 经与会监事审议，以投票表决方式审议通过了以下议案： 1、审议通过《关于增加 2024 年度日常关联交易预计的议案》 监事会认为：公司增加 2024 年度预计发生的日常关联交易事项，是公司正 常业务发展及生产经营所需，是合理和必要的。上述关联交易的定价以市场公允 价格为依据，公平、公正、公开，不存在损害公 ...

证券代码：300937 证券简称：药易购 公告编号：2024-044 四川合纵药易购医药股份有限公司 关于增加 2024 年度日常关联交易预计的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、日常关联交易基本情况 公司于 2024 年 11 月 22 日召开第三届董事会第二十五次会议、第三届监事 会第十八次会议，审议通过了《关于增加 2024 年度日常关联交易预计的议案》， 因股权关系变更，基于审慎原则及公司实际经营情况的需要，同意公司增加 2024 年度日常关联交易预计额度人民币 4,250 万元，包括向重庆鑫斛药房连锁有限公 司（以下简称"鑫斛连锁"）采购商品、销售商品、提供服务，本次增加日常关 联交易预计的期限为自第三届董事会第二十五次会议审议通过之日起至 2024 年 度股东大会召开之日止。 公司独立董事对本议案召开了专门会议并发表了一致同意的审核意见，保荐 机构发表了明确同意的核查意见。根据《深圳证券交易所创业板股票上市规则》 和《公司章程》等有关规定，本次增加日常关联交易预计事项在公司董事会审批 权限范围内，无需提交公司股东大会审议。 （ ...

证券代码：300937 证券简称：药易购 公告编号：2024-038 四川合纵药易购医药股份有限公司 第三届董事会第二十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 四川合纵药易购医药股份有限公司（以下简称"公司"）第三届董事会第二十 四次会议于 2024 年 10 月 24 日在公司会议室以现场结合通讯表决的方式召开。 本次董事会会议通知于 2024 年 10 月 18 日以书面、电话方式通知全体董事。会 议应出席董事 8 名，实际出席董事 8 名，其中独立董事罗响、刘磊、邓博夫以通 讯表决方式出席。本次董事会会议由董事长李燕飞女士主持，公司监事、高级管 理人员列席了本次会议。本次会议的召集和召开符合国家有关法律、行政法规、 部门规章、规范性文件及《四川合纵药易购医药股份有限公司章程》的规定。 二、董事会会议审议情况 经与会董事审议，以投票表决方式审议了以下议案： 1、审议通过《关于公司 2024 年第三季度报告全文的议案》 董事会认为《2024 年第三季度报告》全文的编制和审议程序符合法律法规和 中国证监会、深圳 ...

二、精诚名医的基本情况 （一）基本情况 证券代码：300937 证券简称：药易购 公告编号：2024-040 四川合纵药易购医药股份有限公司 关于控股子公司减资暨少数股东退出的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 四川合纵药易购医药股份有限公司（以下简称"公司"）于 2024 年 10 月 24 日召开第三届董事会第二十四次会议，审议通过了《关于控股子公司减资暨 少数股东退出的议案》。现将有关情况公告如下： 一、本次减资事项概述 公司控股子公司四川精诚名医医疗股份有限公司（以下简称"精诚名医"） 注册资本 2,300 万元，其中公司持有其 51.3209%股权。精诚名医的部分少数股东 成都妙济企业管理合伙企业（有限合伙）（以下简称"成都妙济"）及青曦等三位 自然人股东拟通过减资方式退出，不再持有精诚名医股权，共减少对精诚名医出 资 981.62 万元，减资对价 1,295.03 万元。本次事项不会导致公司合并报表范围 发生变化，公司对精诚名医的出资额不变，本次减资完成后，精诚名医注册资本 将由 2,300 万元减少至 1,318.38 万元，公 ...

Financial Performance - The company's revenue for Q3 2024 was ¥1,010,149,855.81, representing a year-over-year increase of 0.26%[3] - Net profit attributable to shareholders decreased by 46.63% year-over-year to ¥1,835,713.94, while the net profit after deducting non-recurring gains and losses fell by 69.25% to ¥884,089.15[3] - The total operating revenue for the third quarter was CNY 3,235,469,610.27, a slight increase from CNY 3,212,357,594.74 in the previous year, representing a growth of approximately 0.72%[15] - The net profit for Q3 2024 was CNY 10,473,171.26, a decrease from CNY 49,645,720.30 in Q3 2023, representing a decline of approximately 78.9%[16] - The total operating profit for Q3 2024 was CNY 10,234,621.40, down from CNY 60,045,240.85 in the same period last year, indicating a decrease of about 83.0%[16] - The total comprehensive income attributable to the parent company's owners for Q3 2024 was CNY 13,931,460.39, compared to CNY 51,654,269.26 in the same period last year, a decrease of about 73.0%[17] Cash Flow - The operating cash flow for the year-to-date period increased significantly by 129.74% to ¥38,318,291.45[3] - Net cash flow from operating activities improved by 129.74% to ¥38,318,291.45, driven by accelerated customer payments and improved inventory turnover[9] - The cash flow from operating activities for the current period was CNY 2,431,301,554.79, down from CNY 3,107,444,951.09 in the previous year, indicating a decrease of approximately 21.8%[18] - The net cash flow from operating activities for Q3 2024 was 38,318,291.45 CNY, a significant improvement compared to -128,853,482.60 CNY in Q3 2023[19] - The company reported a total cash outflow from operating activities of 2,436,079,170.57 CNY, down from 3,391,258,205.22 CNY in the previous year[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,694,786,201.77, reflecting a 0.46% increase from the previous year[3] - Total liabilities rose to CNY 849,058,831.78 from CNY 831,023,467.80, indicating an increase of approximately 2.7%[15] - The company's non-current assets totaled CNY 318,687,922.33, up from CNY 310,622,601.68, reflecting a growth of about 2.2%[14] Shareholder Information - The total number of common shareholders at the end of the reporting period was 12,860[10] - The largest shareholder, Li Yanfei, holds 36.97% of shares, totaling 35,370,000 shares[11] - The total number of restricted shares at the beginning of the period was 54,371,875, with 21,353,065 shares released during the period[12] Expenses - The company's weighted average return on equity decreased to 0.22%, down by 0.23% compared to the previous year[3] - Financial expenses increased by 84.33% to ¥6,578,010.67 due to higher interest costs from increased borrowings[8] - Other income decreased by 55.81% to ¥1,391,409.14 primarily due to reduced government subsidies[8] - Research and development expenses for Q3 2024 were CNY 12,565,314.67, a slight decrease from CNY 14,122,063.35 in Q3 2023, reflecting a reduction of approximately 11.0%[16] - Sales expenses increased to CNY 180,912,080.87 in Q3 2024, compared to CNY 143,155,370.65 in Q3 2023, marking an increase of about 26.4%[16] Investment Activities - The company reported a net loss from investments of CNY 468,072.44 in Q3 2024, contrasting with a profit of CNY 403,817.23 in Q3 2023[16] - Cash flow from investing activities worsened by 99.79% to -¥24,940,175.33 due to increased investments in principal-protected financial products[9] - Total cash inflow from investing activities was 13,105,813.91 CNY, down from 16,220,277.06 CNY in the previous year[19] Government Subsidies - The company recognized a government subsidy of ¥191,540.64 during the reporting period, contributing to its non-recurring gains[4]

证券代码：300937 证券简称：药易购 公告编号：2024-037 四川合纵药易购医药股份有限公司 关于公司提起上诉暨诉讼进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 四川合纵药易购医药股份有限公司（以下简称"公司"）与杨亚、曹继军、 享健药易购健康科技有限公司（以下简称"享健公司"或"目标公司"）合同纠 纷本诉及反诉一案，公司于 2024 年 8 月 18 日收到广州市黄埔区人民法院出具的 《民事判决书》（（2022）粤 0112 民初 33048 号），具体内容详见公司于 2024 年 8 月 19 日披露的《关于公司收到民事判决书暨诉讼进展公告》（公告编号： 2024-034）。公司因不服一审判决，依法向广州市中级人民法院提起上诉，并于 近日收到广州市黄埔区人民法院送达的杨亚、曹继军、享健公司的《上诉状》。 现将有关情况公告如下： 一、公司提交上诉的基本情况 （一）案件当事人 3、判令被上诉人共同承担本案诉讼费。 二、对方提交上诉的基本情况 （一）案件当事人 上诉人：杨亚、曹继军、享健药易购健康科技有限公司 被上诉人：四川合纵药易购医药股份 ...

| 保荐人名称：申万宏源证券承销保荐有限责任公司 | 被保荐公司简称：药易购（300937） | | --- | --- | | 保荐代表人姓名：罗泽 | 联系电话：028-85958793 | | 保荐代表人姓名：何搏 | 联系电话：028-85958796 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 | | 2.督导公司建立健全并有效执行规章制度的情 | | | 况（1）是否督导公司建立健全规章制度（包括但 | | | 不限于防止关联方占用公司资源的制度、募集 | 是 | | 资金管理制度、内控制度、内部审计制度、关 | | | 联交易制度） （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 募集资金已于2023年使用完毕并销户 | | （2）公司募集资金项目进展是否与信息披露文 | 是 | | 件一致 | | | 4.公司治理督导情况 | | | （1）列席公 ...

证券代码：300937 证券简称：药易购 公告编号：2024-036 四川合纵药易购医药股份有限公司 关于会计政策变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 四川合纵药易购医药股份有限公司（以下简称"公司"）依据中华人民共和 国财政部（以下简称"财政部"）发布的相关企业会计准则解释及规定要求变更 会计政策。根据《深圳证券交易所创业板股票上市规则》有关规定，本次会计政 策变更无需提交公司董事会及股东大会审议，现将具体情况公告如下： 一、会计政策变更情况概述 （一）变更原因 1、2023 年 8 月 1 日，财政部发布了《关于印发<企业数据资源相关会计处 理暂行规定>的通知》（财会〔2023〕11 号）（以下简称"《暂行规定》"）， 规定"企业数据资源相关会计处理"的内容，自 2024 年 1 月 1 日起施行。 （二）变更前采用的会计政策 本次会计政策变更前，公司执行财政部发布的《企业会计准则——基本准则》 和各项具体会计准则、企业会计准则应用指南、企业会计准则解释公告以及其他 相关规定。 （三）变更后采用的会计政策 本次会计政策变更后，公司将执 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion yuan for the first half of 2024, representing a year-over-year growth of 15%[4]. - The company's operating revenue for the first half of 2024 was CNY 2,225,319,754.46, representing a 0.93% increase compared to CNY 2,204,845,065.75 in the same period last year[15]. - In the first half of 2024, the company's revenue reached 2.225 billion yuan, a year-on-year increase of 0.93%, while net profit attributable to shareholders was 12.0957 million yuan, a decline of 74.11%[22]. - The company's net profit attributable to shareholders decreased by 74.11% to CNY 12,095,746.45 from CNY 46,717,668.57 in the previous year[15]. - The total comprehensive income for the first half of 2024 was CNY 23,372,979.02, down from CNY 51,287,749.46 in the first half of 2023, representing a decrease of approximately 54.4%[142]. - The company's net profit for the first half of 2024 was ¥8,831,979.09, down from ¥56,989,412.01 in the previous year, marking a decrease of around 84.5%[138]. - The company's basic and diluted earnings per share fell by 73.47% to CNY 0.13 from CNY 0.49 in the previous year[15]. - The company reported a significant decline in non-recurring profit and loss, with a net profit of CNY 8,481,216.66, down 80.80% from CNY 44,163,173.51 in the previous year[15]. User Growth and Market Expansion - User data indicates a growth in active users, reaching 5 million, which is a 20% increase compared to the same period last year[4]. - The company is expanding its market presence, targeting an increase in the number of retail locations by 25% over the next year[4]. - The company has established partnerships with over 1,800 pharmaceutical manufacturers, holding more than 12,000 pharmaceutical product distribution qualifications[24]. - The company aims to enhance its C-end reach and develop a new industrial model to improve pricing power and create a series of high-quality pharmaceutical products[22]. - The company is focusing on risk control in emerging business development, managing costs, and improving funding management during the cultivation period of the second growth curve[22]. Strategic Initiatives - The company has provided a positive outlook for the second half of 2024, projecting a revenue growth of 10% to 15%[4]. - New product launches are expected to contribute an additional 200 million yuan in revenue by the end of 2024[4]. - The company plans to pursue strategic acquisitions to bolster its market position, with a budget of 500 million yuan allocated for potential deals[4]. - The company is actively investing in internet pharmaceutical retail projects, including the establishment of a B2C e-commerce operation base in Hangzhou[28]. - The company is exploring potential mergers and acquisitions to strengthen its market position[151]. Financial Management and Investments - Investment in new technology development has increased by 30%, focusing on enhancing supply chain efficiency[4]. - The company has established a credit system for small and micro customers, granting credit to 1,534 customers with a total credit amount of 25.53 million yuan during the reporting period[30]. - The company has set up a private equity fund to accelerate resource integration and investment opportunities in the pharmaceutical industry[29]. - The company has recognized data resources as intangible assets on the balance sheet, with a book value of 1,939,429.99 yuan as of the end of the reporting period[30]. - The company reported a total of 3,271.65 million CNY in related party transactions during the reporting period, with a maximum approved transaction amount of 19,320 million CNY[103]. Operational Challenges - The company has identified key risks, including intensified market competition and regulatory changes, which may impact future performance[3]. - The company's gross profit margin has decreased, influenced by a decline in retail scale in the pharmaceutical terminal market and a high comparable base from the previous year due to a public health event[22]. - The B2B e-commerce platform has seen a decrease in monthly active customers, leading to a decline in revenue, affected by regulatory requirements for unified management of retail chain headquarters[22]. - The company faces intensified market competition and changing demand, necessitating increased investment in promotions and R&D, which may not yield expected results[78]. Cash Flow and Financial Position - The net cash flow from operating activities improved significantly, reaching CNY 3,376,800.31, compared to a negative CNY 87,880,002.16 in the same period last year, marking a 103.84% increase[15]. - The company's cash and cash equivalents decreased by 72.43% to -¥55,734,803.18, mainly due to accelerated customer collections and improved inventory turnover[50]. - The total cash inflow from operating activities was CNY 1,714,242,712.44 in the first half of 2024, down from CNY 2,064,085,285.80 in the first half of 2023, representing a decrease of approximately 16.9%[143]. - The company reported a cash outflow of ¥1.45 billion for purchasing goods and services in the first half of 2024, compared to ¥1.89 billion in the previous year, reflecting a decrease of approximately 23.1%[145]. Corporate Governance and Compliance - The company has established a comprehensive management system and enhanced its internal processes to support long-term strategic development[43]. - The company emphasizes strict compliance with e-commerce laws and consumer protection regulations to mitigate risks in information security and business ethics[42]. - The company has maintained a commitment to transparency and accurate information disclosure, ensuring that shareholders are informed of significant matters[90]. - The financial report was approved by the board on August 27, 2024, ensuring compliance with accounting standards[160]. Research and Development - The company aims to enhance its research and development capabilities to drive future growth[151]. - Research and development investment decreased by 10.13% to ¥11,033,371.43, primarily due to reduced MAH R&D expenditures[50]. - The company has initiated research and development for new technologies aimed at enhancing operational efficiency and product offerings[180]. - The company is focusing on research and development of new products to strengthen its market position[159].

证券代码：300937 证券简称：药易购 公告编号：2024-034 四川合纵药易购医药股份有限公司 关于公司收到民事判决书暨诉讼进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 公司近日收到广州市黄埔区人民法院出具的《民事判决书》（（2022）粤 0112 民初 33048 号），判决如下： 1、案件所处的诉讼阶段：一审判决； 2、公司所处的当事人地位：被告、反诉原告； 3、涉案的金额：判决金额人民币 4,400 万元及相关费用； 4、对公司损益产生的影响：本次判决为一审判决，最终诉讼、执行结果及 对公司本期及期后利润的影响存在不确定性，敬请投资者注意投资风险。 一、本次诉讼事项的基本情况 四川合纵药易购医药股份有限公司（以下简称"公司"）于 2022 年 11 月 10 日收到广东省广州市黄埔区人民法院送达的《民事起诉状》《应诉通知书》等 法律文书，原告杨亚、曹继军以公司为被告提起民事诉讼，具体内容详见公司在 巨潮资讯网（www.cninfo.com.cn）披露的《关于公司收到民事起诉状的公告》（公 告编号：2022-072）。 原 ...